People with SARS-CoV-2 antibodies, a sign of prior infection, were much less likely to test positive for COVID-19 in the following months.

Researchers found that fine particulate matter levels in the air of subway systems across the Northeastern U.S exceed air safety standards.

A combination of two monoclonal antibodies prevented and effectively treated Middle East Respiratory Syndrome (MERS) in mice.